Patents by Inventor Jeffery ARDINGER

Jeffery ARDINGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220340883
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Application
    Filed: March 3, 2022
    Publication date: October 27, 2022
    Inventors: Peter PECHAN, Jeffery ARDINGER, Abraham SCARIA, Samuel WADSWORTH
  • Patent number: 11351807
    Abstract: A method of stenciling a stenciled graphic in a desired position and orientation on the graphic-display surface of a substrate includes providing at least one stencil template defining the stenciled graphic and at least one guide element including mutually-space template positioning indicia. Both the stencil template and the guide element are magnetically attracted to the substrate. The guide element is magnetically affixed to the graphic display surface in a desired location and orientation. The stencil template is magnetically affixed to the graphic-display surface in a location selected with positioning reference to at least one template-positioning indicium of the guide element. With or without the guide element still affixed, pigment is applied to the graphic-display surface through the at least one stencil template to impart to the graphic-display surface the desired stenciled graphic. The at least one stencil template is then removed from the graphic-display surface.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: June 7, 2022
    Inventors: Karen Ardinger, Jeffery Ardinger
  • Patent number: 11299715
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2022
    Assignee: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Publication number: 20220064262
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 3, 2022
    Applicants: Genzyme Corporation, Genzyme Corporation
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Patent number: 11084864
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 10, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Patent number: 10821193
    Abstract: Provided herein are methods for treating myocilin (MYOC) glaucoma using adeno-associated viral (AAV) vectors. In some aspects, the AAV vectors encode R-spondin 1 (RSPO1), R-spondin 2 (RSPO2), R-spondin 3 (RSPO3) or R-spondin 4 (RSPO4) and/or RNAi that targets myocilin (MYOC). In one aspect, viral particles are administered to the eye of a human subject. Viral particles encoding RSPO1, RSPO2, RSPO3 and/or RSPO4 and/or MYOC RNAi are contemplated. In some aspects, variant AAV2 particles that transduce the trabecular meshwork are provided.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: November 3, 2020
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Abraham Scaria, Jeffery Ardinger
  • Publication number: 20200139740
    Abstract: A method of stenciling a stenciled graphic in a desired position and orientation on the graphic-display surface of a substrate includes providing at least one stencil template defining the stenciled graphic and at least one guide element including mutually-space template positioning indicia. Both the stencil template and the guide element are magnetically attracted to the substrate. The guide element is magnetically affixed to the graphic display surface in a desired location and orientation. The stencil template is magnetically affixed to the graphic-display surface in a location selected with positioning reference to at least one template-positioning indicium of the guide element. With or without the guide element still affixed, pigment is applied to the graphic-display surface through the at least one stencil template to impart to the graphic-display surface the desired stenciled graphic. The at least one stencil template is then removed from the graphic-display surface.
    Type: Application
    Filed: November 5, 2019
    Publication date: May 7, 2020
    Inventors: Karen Ardinger, Jeffery Ardinger
  • Publication number: 20190345223
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: November 20, 2018
    Publication date: November 14, 2019
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Patent number: 10183983
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: January 22, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Publication number: 20170342127
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 28, 2017
    Publication date: November 30, 2017
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20170304465
    Abstract: Provided herein are methods for treating myocilin (MYOC) glaucoma using adeno-associated viral (AAV) vectors. In some aspects, the AAV vectors encode R-spondin 1 (RSPO1), R-spondin 2 (RSPO2), R-spondin 3 (RSPO3) or R-spondin 4 (RSPO4) and/or RNAi that targets myocilin (MYOC). In one aspect, viral particles are administered to the eye of a human subject. Viral particles encoding RSPO1, RSPO2, RSPO3 and/or RSPO4 and/or MYOC RNAi are contemplated. In some aspects, variant AAV2 particles that transduce the trabecular meshwork are provided.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 26, 2017
    Inventors: Peter PECHAN, Abraham SCARIA, Jeffery ARDINGER
  • Patent number: 9637534
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 2, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Publication number: 20150353899
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 10, 2015
    Applicant: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA